Pure Global
NCT06227221

A Phase 2, Randomized, Placebo Controlled Study Investigating the Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus

Second Xiangya Hospital of Central South University·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Type 1 Diabetes
Drug/Device/Intervention
Sorafenib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Second Xiangya Hospital of Central South University
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Dec 01, 2026
Enrollment
60 participants
Primary outcome

The primary endpoint of the study is the change from baseline of serum C-peptide area under the curve (AUC) over 2 hours following a mixed meal

Summary

The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in
 T1DM patients.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06227221
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06227221 through Pure Global AI's free database. This Phase 2 trial is sponsored by Second Xiangya Hospital of Central South University and is currently Not yet recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.